However, a double-blind, randomized, placebo-controlled, 12-week trial using an IL-1 inhibitor provided the first evidence that IL-1 inhibition improves endothelial-dependent dilation (EDD), a crucial predictor of future cardiovascular events and associated mortality in patients with moderate to severe CKD who do not require chronic dialysis [64]. Here, IL1B is linked to chronic kidney disease.